



Comparison of clinical and radiological outcomes of vertebral body stenting versus percutaneous kyphoplasty for the treatment of osteoporotic vertebral compression fracture: A systematic review and meta-analysis

Ting Zhang, PhD^{1*}, Yinxiao Peng, MD^{2*}, Jun Li, PhD²

¹Center of Obesity and Metabolic Diseases, Department of General Surgery, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China

²Department of Orthopaedic, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China

Osteoporotic vertebral compression fractures (OVCFs) are common in the aging population, and there are approximately 1.7 million cases of OVCF in the USA and Europe annually. Percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) are well-established methods for treating OVCFs.^[1-3] Percutaneous kyphoplasty is considered a second-generation minimally invasive alternative to PVP due to its advantages in correcting Cobb angle and reducing cement leakage.^[4-6] However, studies have shown that PKP does not significantly improve vertebral body height and Cobb angle in

Received: August 02, 2023 Accepted: September 05, 2023 Published online: November 23, 2023

Correspondence: Jun Li, PhD. Department of Orthopaedic, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610031, China.

E-mail: junli@swjtu.edu.cn

Doi: 10.52312/jdrs.2023.1356

* The authors contributed equally to this study

Citation: Zhang T, Peng Y, Li J. Comparison of clinical and radiological outcomes of vertebral body stenting versus percutaneous kyphoplasty for the treatment of osteoporotic vertebral compression fracture: A systematic review and meta-analysis. Jt Dis Relat Surg 2024;35(1):218-230. doi: 10.52312/ jdrs.2023.1356.

©2024 All right reserved by the Turkish Joint Diseases Foundation

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (http://creativecommons.org/licenses/by-nc/4.0/).

ABSTRACT

Objectives: The study aimed to compare the efficacy and safety of percutaneous kyphoplasty (PKP) and vertebral body stenting (VBS) in the treatment of osteoporotic vertebral compression fractures (OVCFs) and evaluate the clinical efficacy, Cobb angle correction, and cement leakage associated with both methods for OVCFs.

Materials and methods: A systematic search was conducted in PubMed, EMBASE, Cochrane Library, Medline, China National Knowledge, and Wanfang Data for clinical studies comparing VBS with PKP for OVCF up to May 2023. The meta-analysis was performed using Review Manager 5.3, with a focus on evaluating clinical and radiologic outcomes.

Results: A total of eight eligible clinical studies were included in this meta-analysis. In terms of clinical outcomes, VBS was found to have a longer surgical time compared to PKP (standard mean difference [SMD]=1.06 min; 95% confidence interval [CI]: 0.20, 1.92; p=0.02). However, VBS demonstrated comparable blood loss to PKP (SMD =0.00 mL; 95% CI: -0.45, 0.45; p=0.99). Additionally, VBS showed slight superiority in alleviating back pain as measured by the Visual Analog Scale (VAS) (SMD=-0.38; 95% CI: -0.63, -0.12; p=0.004), as well as in improving functional disability based on the Oswestry Disability Index (ODI) (SMD= -0.28; 95% CI: -0.54, -0.03; p=0.03). Radiographically, VBS achieved better Cobb angle correction compared to PKP (SMD=-1.00; 95% CI: -1.48, -0.51; p<0.0001), while there was no significant difference in cement leakage between VBS and PKP (odds ratio=0.81; 95% CI: 0.21, 3.14; p=0.76).

Conclusion: The findings suggest that VBS has a comparable clinical outcome to PKP based on operation time, intraoperative blood loss, VAS, and ODI. Furthermore, VBS showed slightly better maintenance of Cobb angle correction, whereas VBS did not demonstrate a significant advantage over PKP in terms of cement leakage.

Keywords: Meta-analysis, osteoporosis vertebral compression fracture, percutaneous kyphoplasty, vertebral body stenting.

OVCF due to the deflation of the balloon before cement perfusion.^[7,8] Additionally, PKP is not effective in reducing endplate fractures, which are an independent risk factor for adjacent segment degeneration and the development of new symptomatic OVCF.^[3,9]

Muto et al.^[10] first reported the use of a vertebral body stenting (VBS) system for treating OVCF. They discovered that VBS effectively reduced vertebral body collapse and achieved significant height restoration (Figure 1). However, the superiority of VBS over PKP remains controversial. Several studies have demonstrated that VBS outperforms PKP in terms of kyphosis correction and reduction of vertebral body height.^[11-15] Nonetheless, Werner et al.^[16] conducted a randomized trial and found no beneficial effect of VBS over PKP regarding kyphotic correction, cement leakage, radiation time exposure, or neurologic injury. Hence, we performed a meta-analysis to evaluate whether VBS is indeed superior to PKP in the treatment of OVCF, with the aim of providing substantial evidence for clinical decision-making.

MATERIALS AND METHODS

Search strategy

A systematically literature search was conducted in PubMed, EMBASE, Cochrane Library, Medline, China National Knowledge Internet, and Wanfang Data up to May 2023. The study was registered with PROSPERO (registration number CRD42023430990). No other systematic reviews focusing on VBS and PKP for OVCF were found in the PROSPERO database. The search strategy used the following formula: ((((vertebral body stenting system[Title/Abstract])) OR (VBS[Title/Abstract])) OR (vertebral body stenting[Title/Abstract])) OR (vertebral stenting[Title/ Abstract])) OR (vertebral body stent system[Title/ Abstract])) AND (((((percutaneous kyphoplasty[Title/



FIGURE 1. Schematic diagram illustrating PKP and VBS surgical procedures. **(a-d)**, schematic diagram of PKP surgical steps. **(e-h)**, schematic diagram of VBS surgical steps. PKP: Percutaneous kyphoplasty; VBS: Vertebral body stenting.

Abstract]) OR (PKP[Title/Abstract])) OR (percutaneous balloon kyphoplasty[Title/Abstract])) OR (BKP[Title/ Abstract])) OR (kyphoplasty[Title/Abstract])) OR (vertebral balloon plasty[Title/Abstract]))) AND (((((osteoporosis vertebral compression fracture[Title/ Abstract]) OR (OVCF[Title/Abstract])) OR (OVF[Title/ Abstract]))OR(osteoporosiscompressionfracture[Title/ Abstract])) OR (osteoporotic fracture[Title/Abstract])) OR (osteoporotic vertebral fracture[Title/Abstract])).

The inclusion criteria for the publications were as follows: (i) participants were aged ≥ 18 years with OVCF, excluding non-OVCF or traumatic vertebral fracture; (ii) a comparison was made between the intervention methods of VBS and PKP; (iii) outcome parameters included operation time, blood loss, Oswestry Disability Index (ODI), Visual Analog Scale (VAS), Cobb angle, and cement leakage; (v) the study design was either a randomized controlled trial (RCT) or a cohort study. The exclusion criteria were as follows: (i) a comparison between VBS and PVP; (ii) duplicate articles or articles including the same patients and results; (iii) studies conducted on animals or cadavers.

Data extraction

Identification

According to the inclusion and exclusion criteria, two researchers independently screened the literature

Records screeded after title

Records identified through

database searching

(n=228)

Jt Dis Relat Surg

Statistical analysis

All extracted data were analyzed using Review Manager (RevMan version 5.3; Cochrane Collaboration, Oxford, UK). Heterogeneity was assessed using the I^2 statistic. An $I^2 < 50\%$ indicated no significant homogeneity among studies, and *p*-value <0.05 was considered statistically significant.

RESULTS

acquired from the databases and nine from other sources. After screening for duplication, nonclinical



Additional records through

other sources

(n=9)

Search results A total of 237 studies were identified, with 228



Image: Characteristics of the included studies in the meta-analysis Anarcteristics of the included studies in the meta-analysis Sample size (n) Mean age (rear) Sample size (n) Mean age (rear) Anarcteristics of the included studies in the meta-analysis Sample size (n) Mean age (rear) Sample size (n) Mean age (rear) Anarcteristics of the included studies (proving trained studies (pr				TA	BLE I						
Ind yearLocationStudy periodStudy designDiagnosisVBSMean age (year)Mean age (year)rd yearLocationStudy periodStudy designDiagnosisVBSPKPFollow upNOSet al. ¹¹⁶¹ (2014)SwizerlandNDRandomized control trialOVCF5050NDNDPostoperationNA. ²²¹ (2018)China2014.1-2017.12Retrospective cohort studyOVCF202465.50±7.9869.67±6.9866. ¹¹¹ (2020)China2014.1-2018.12Retrospective cohort studyOVCF152576.8±9.9272.84±7.53ND7. ¹²¹ (2022)China2014.1-202.11Retrospective cohort studyOVCF167072.3±9.774.6±9.466. ¹²¹ (2022)China2019.1-202.01Retrospective cohort studyOVCF197076.28±3.777.03±3.067. ¹²¹ (2022)China2019.1-202.01Retrospective cohort studyOVCF1976.28±3.777.03±3.067. ¹²¹ (2022)China2019.1-202.01Retrospective cohort studyOVCF1976.28±3.777.03±3.067. ¹²¹ (2022)China2019.1-202.01Retrospective cohort studyOVCF1976.28±3.777.03±3.067. ¹²¹ (2022)China2019.1-202.01Retrospective cohort studyOVCF1976.28±3.777.03±3.30147. ¹²¹ (2022)Ch				Characteristics of the include	ed studies in	the meta-	analysis				
Ind yearLocationStudy periodStudy designDiagnosisVBSPKPFollow upNOet al. ¹⁶¹ (2014)SwizerlandNDRandomized control trialOVCF5050NDNDPostoperationNA $I.^{123}(2018)$ China2014.1-2017.12Retrospective cohort studyOVCF502465.50.7.3869.67.46.9866 $I.^{123}(2020)$ China2017.1-2018.12Retrospective cohort studyOVCF152576.84.9.9272.84.47.53ND7 $I.^{123}(2022)$ China2017.1-2020.12Retrospective cohort studyOVCF191976.284.3777.033.3067 $I.^{123}(2022)$ China2019.1-2020.12Retrospective cohort studyOVCF191976.284.3777.033.3067 $I.^{123}(2022)$ China2019.1-2020.12Retrospective cohort studyOVCF303269.004.2.6369.414.2.3077 $I.^{113}(2022)$ China2019.1-2020.12Retrospective cohort studyOVCF307276.284.3777.033.3067 $I.^{113}(2022)$ China2019.1-2020.12Retrospective cohort studyOVCF307276.284.3777.034.30067 $I.^{113}(2022)$ China2019.1-2020.12Retrospective cohort studyOVCF307276.684.3777.034.30067 $I.^{113}(2022)$ China2019.1-2020.12Retrospective cohort study <td< th=""><th></th><th></th><th></th><th></th><th></th><th>Sample</th><th>size (n)</th><th>Mean ag</th><th>je (year)</th><th></th><th></th></td<>						Sample	size (n)	Mean ag	je (year)		
et al. $^{1/61}$ SwizerlandNDRandomized control trialOVCF5050NDNDPostoperationNA $.1^{2/3}$ (2018)China2014.1-2017.12Retrospective cohort studyOVCF202465.50±7.9869.67±6.98666 $.1^{1/11}$ (2020)China2017.1-2018.12Retrospective cohort studyOVCF152576.8±9.9272.84±7.53ND77 $.1^{1/11}$ (2022)China2017.1-2018.12Retrospective cohort studyOVCF197072.3±9.774.6±9.466 $.1^{1/21}$ (2022)China2019.1-2020.12Retrospective cohort studyOVCF1976.28±3.777.03±3.067* $.1^{1/21}$ (2022)China2019.1-2020.12Retrospective cohort studyOVCF197976.28±3.777.03±3.067* $.1^{1/21}$ (2022)China2019.1-2020.12Retrospective cohort studyOVCF303269.00±2.6368.41±2.30147* $.1^{1/21}$ (2023)China2019.7-2020.12Retrospective cohort studyOVCF303269.00±2.6368.41±2.30147* $.1^{1/21}$ (2023)China2019.7-2020.12Retrospective cohort studyOVCF364768.78±6.237*7*7* $.1^{1/21}$ (2023)China2019.7-2020.12Retrospective cohort studyOVCF364768.78±6.237*7*	and year	Location	Study period	Study design	Diagnosis	VBS	РКР	VBS	РКР	Follow up (month)	NOS
II. ^{I23} (2018) China 2014.1-2017.12 Retrospective cohort study OVCF 20 24 65.50 ± 7.98 69.67 ± 6.98 6 6^{*} $al.^{I1/1}(2020)$ China $2017.1-2018.12$ Retrospective cohort study OVCF 15 25 76.8 ± 9.92 72.8 ± 7.53 ND 7^{*} $al.^{I23}(2022)$ China $2007.1-2028.11$ Retrospective cohort study OVCF 40 40 72.3 ± 9.7 74.6 ± 9.4 6 6 6 6 7 $al.^{I23}(2022)$ China $2019.1-2020.12$ Retrospective cohort study OVCF 40 40 72.3 ± 9.7 71.03 ± 3.0 6 6 7 $t al.^{I24}(2022)$ China $2019.1-2020.12$ Retrospective cohort study OVCF 19 76.28\pm3.7 77.03 ± 3.0 6 7 $t al.^{I24}(2022)$ China $2019.1-2020.1$ Retrospective cohort study OVCF 30 32 69.00\pm2.63 68.41\pm2.30 14 7 $t al.^{I24}(2023)$ China $2019.7-2020.12$	r et al. ^[16] (2014)	Swizerland	QN	Randomized control trial	OVCF	50	50	QN	QN	Postoperation	NA
al. ^[11] (2020) China 2017.1-2018.12 Retrospective cohort study OVCF 15 25 76.8±9.92 72.84±7.53 ND 7* al. ^[23] (2022) China 200.1-202.1 Retrospective cohort study OVCF 40 40 72.3±9.7 74.6±9.4 6 6* et al. ^[24] (2022) China 2019.1-2020.12 Retrospective cohort study OVCF 19 19 76.28±3.7 77.03±3.0 6 7* et al. ^[24] (2022) China 2019.1-2020.12 Retrospective cohort study OVCF 30 32 69.00±2.63 68.41±2.30 14 7* et al. ^[24] (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 30 32 69.00±2.63 68.41±2.30 14 7* et al. ^[24] (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.231 67.0±2.33 >12 7* et al. ^[24] (2023) China	al. ^[22] (2018)	China	2014.1-2017.12	Retrospective cohort study	OVCF	20	24	65.50±7.98	69.67±6.98	9	*9
al. 123 (2022) China 2020.1-2022.1 Retrospective cohort study OVCF 40 72.3±9.7 74.6±9.4 6 6* et al. 124 (2022) China 2019.1-2020.12 Retrospective cohort study OVCF 19 19 76.28±3.7 77.03±3.0 6 7* et al. 124 (2022) China 2019.1-2020.12 Retrospective cohort study OVCF 30 32 69.00±2.63 68.41±2.30 14 7* et al. 121 (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.281 67.81±6.233 7* et al. 121 (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.281 67.81±6.233 7* et al. 121 (2023) China 2020.3-2022.3 Retrospective cohort study OVCF 36 47 68.76±16.335 712 7*	al. ^[11] (2020)	China	2017.1-2018.12	Retrospective cohort study	OVCF	15	25	76.8±9.92	72.84±7.53	QN	7*
et al. ^[24] (2022) China 2013.1-2020.12 Retrospective cohort study OVCF 19 19 76.28±3.7 77.03±3.0 6 7* 14. ^[12] (2022) China 2019.1-2020.1 Retrospective cohort study OVCF 30 32 69.00±2.63 68.41±2.30 14 7* et al. ^[21] (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.281 67.81±6.233 >12 7* at al. ^[23] (2023) China 2020.3-2022.3 Retrospective cohort study OVCF 55 55 74.61±3.38 75.02±3.95 ND 7*	al. ^[23] (2022)	China	2020.1-2022.1	Retrospective cohort study	OVCF	40	40	72.3±9.7	74.6±9.4	9	*9
t al. ^{1/13} (2022) China 2019.1-2020.1 Retrospective cohort study OVCF 30 32 69.00±2.63 68.41±2.30 14 7* et al. ^[21] (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.281 67.81±6.233 >12 7* st al. ^[23] (2023) China 2020.3-2022.3 Retrospective cohort study OVCF 55 55 74.61±3.38 75.02±3.95 ND 7*	et al. ^[24] (2022)	China	2019.1-2020.12	Retrospective cohort study	OVCF	19	19	76.28±3.7	77.03±3.0	9	7*
et al. ^[21] (2023) China 2019.7-2020.12 Retrospective cohort study OVCF 36 47 68.78±6.281 67.81±6.233 >12 7* t al. ^[29] (2023) China 2020.3-2022.3 Retrospective cohort study OVCF 55 55 74.61±3.38 75.02±3.95 ND 7*	et al. ^[12] (2022)	China	2019.1-2020.1	Retrospective cohort study	OVCF	30	32	69.00±2.63	68.41±2.30	14	7*
it al. ^[25] (2023) China 2020.3-2022.3 Retrospective cohort study OVCF 55 55 74.61±3.38 75.02±3.95 ND 7*	et al. ^[21] (2023)	China	2019.7-2020.12	Retrospective cohort study	OVCF	36	47	68.78±6.281	67.81±6.233	>12	7*
	rt al. ^[25] (2023)	China	2020.3-2022.3	Retrospective cohort study	OVCF	55	55	74.61±3.38	75.02±3.95	QN	7*

trials, reviews, meta-analyses, and other criteria, 236 studies were excluded based on title and abstract.

The full text of the remaining 31 studies was reviewed, and 19 additional studies were excluded for various reasons. Ultimately, eight studies were included in the present study. The flowchart depicting the literature selection process is presented in Figure 2.

Characteristics of studies

The eight included studies, published between 2014 and 2023, comprised one RCT and seven retrospective cohort studies. Based on the Newcastle-Ottawa Scale (NOS) assessment, all the studies were considered moderate-to-high quality. The total sample size consisted of 557 patients, with 265 in the VBS group and 292 in the PKP group. All patients were diagnosed with OVCF. The basic characteristics of the included studies are summarized in Table I.

Evaluation of literature quality

The quality of RCTs was evaluated using a modified version of the generic assessment tool as outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Figure 3). The NOS system was used to assess the quality of non-RCTs based on study population selection, comparability of parameters, and outcomes evaluation. Studies with more than five "stars" were included in the analysis (Table I).



Meta-analysis results

Clinical outcomes

In terms of clinical outcomes, among the seven articles comparing the operation time of VBS and PKP, the meta-analysis included 215 patients in the VBS group and 242 patients in the PKP group. Vertebral body stenting was found to have a slightly longer surgical time compared to PKP (SMD=1.06 min; 95% CI: 0.20, 1.92; p=0.02; heterogeneity: Tau² =1.26, Chi²=101.99, degrees of freedom [df]=6, p<0.01, $I^2=94\%$; Figure 4a). In the five articles comparing intraoperative blood loss between VBS and PKP, a total of 165 patients were included in the VBS group and 186 patients in the PKP group. The results of the meta-analysis revealed no significant difference in blood loss between the two groups (SMD=0.00 mL; 95% CI: -0.45, 0.45; p=0.99; heterogeneity: Tau²=0.20, Chi²=16.85, df=4, p<0.01, *I*²=94%; Figure 4b).

Visual Analog Scale for back pain was reported in seven articles. Among the six studies reporting preoperative VAS for back pain, no significant difference was observed (SMD= -0.03; 95% CI: -0.22, 0.16; p>0.05; heterogeneity: Tau²=0.00, Chi²=2.52, df=5, p>0.05, *I*²=0%). There were five, two, two, and seven studies that reported VAS for back pain at three postoperative days, one postoperative month, three postoperative months, and the final follow-up, respectively. Meta-analysis showed no significant difference at any of these time points. However, when tested for the overall effect, VBS showed slight superiority in alleviating back pain as measured by VAS (SMD= -0.38; 95% CI: -0.63, -0.12; p=0.004; Figure 5).

There were two, three, five, and two studies that reported outcome data for ODI at three postoperative days, one postoperative month, three postoperative months, and the final follow-up time, respectively. Meta-analysis revealed no significant difference at three days, three months, and the last follow-up postoperatively. However, VBS showed a slight improvement in ODI compared to PKP at one month (SMD= -0.81; 95% CI: -1.27, -0.35; p<0.05; heterogeneity: Tau²=0.03, Chi²=1.35, df=1, p>0.05, I²=26%). In the test for overall effect, VBS demonstrated a slight advantage in improving functional disability as measured by the ODI (SMD= -0.28; 95% CI: -0.54, -0.03; p=0.03; Figure 6). Clinically, the slight difference in operation time, VAS, and ODI between the two methods was almost negligible.

(a) Operation time (minutes)

		VBS			РКР		S	itd. Mean Difference		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI	
2018 Jia P.	23.85	5.08	20	22.96	4.28	24	14.3%	0.19 [-0.41, 0.78]		-	
2020 Ma Y. H.	41.2	7.89	15	37.08	7.08	25	14.1%	0.55 [-0.11, 1.20]		-	
2022 Xia K. Y.	33.61	7.31	40	25.76	2.43	40	14.6%	1.43 [0.93, 1.92]		-	
2022 Zhang P. W.	40.1	7.5	19	38.71	8.1	19	14.1%	0.17 [-0.46, 0.81]		+	
2022 Zhao P.	26.8	3.53	30	25.34	2.73	32	14.6%	0.46 [-0.05, 0.96]		-	
2023 Wang H. J.	63.22	4.32	36	47.38	2.52	47	13.4%	4.59 [3.76, 5.43]			
2023 Zhao Z. N.	40.8	9	55	38.4	7	55	14.9%	0.30 [-0.08, 0.67]		-	
Total (95% CI)			215			242	100.0%	1.06 [0.20, 1.92]		•	
Heterogeneity: Tau ² =	= 1.26; 0	$Chi^2 =$	101.99	, df = 6	(P < 0	0.0000	1); $I^2 = 949$	%	-10	-5 0 5	10
lest for overall effect	Z = 2.4	+2 (P =	= 0.02)							Favours [VBS] Favours [PKP]	

(b) Blood loss (mL)

	Expe	rimen	ital	C	ontrol		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2020 Ma Y. H.	1.73	1.53	15	2.44	1.66	25	17.3%	-0.43 [-1.08, 0.22]	
2022 Xia K. Y.	6.91	2.24	40	5.43	1.12	40	21.0%	0.83 [0.37, 1.29]	
2022 Zhang P. W.	8.52	1.98	19	8.76	1.56	19	17.5%	-0.13 [-0.77, 0.50]	
2023 Wang H. J.	2	0.34	36	2.01	0.3	47	21.5%	-0.03 [-0.47, 0.40]	LOLE
2023 Zhao Z. N.	2.09	0.33	55	2.21	0.46	55	22.6%	-0.30 [-0.67, 0.08]	
Total (95% CI)			165			186	100.0%	0.00 [-0.45, 0.45]	-
Heterogeneity: Tau ² =	= 0.20; 0	Chi ² =	16.85,	df = 4	(P = 0)	.002); I	$^{2} = 76\%$		
Test for overall effect	: Z = 0.0)1 (P =	= 0.99)	Favours[VBS] Favours[PKP]					

FIGURE 4. Forest plots comparing the operation time and blood loss between VBS and PKP. VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; SD: Standard deviation; CI: Confidence interval.

Radiologic outcomes

Cobb angle was reported in six articles, with Cobb angle measurements available at different time points. Specifically, six articles reported Cobb angle before the operation, four articles at three postoperative days, two articles at one postoperative

VAS Std. Mean Difference VBS PKP Std. Mean Difference Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI Study or Subgroup 4.2.1 preoperation VAS 2018 Jia P. 7.65 0.59 4.4% -0.09 [-0.68, 0.51] 20 7.71 0.75 24 0.12 [-0.32, 0.56] 2022 Xia K. Y. 7.95 0.59 7.88 0.57 40 5.0% 40 2022 Zhang P. W. 6.13 0.72 19 6.15 0.66 19 4.3% -0.03 [-0.66, 0.61] 2022 Zhao P. 7.57 0.85 30 7.5 0.88 32 4.8% 0.08 [-0.42, 0.58] 2023 Wang H. J. 8.25 0.65 36 8.45 0.58 47 5.0% -0.32 [-0.76, 0.11] 2023 Zhao Z. N. 8.12 1.95 55 8.05 2.01 55 5.2% 0.04 [-0.34, 0.41] Subtotal (95% CI) 200 217 28.5% -0.03 [-0.22, 0.16] Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 2.52$, df = 5 (P = 0.77); $I^2 = 0\%$ Test for overall effect: Z = 0.31 (P = 0.76) 4.2.2 3 days postoperation 2018 Jia P. 2.4 0.82 20 2.25 0.74 24 4.4% 0.19 [-0.41, 0.78] 2020 Ma Y. H. 1.64 0.64 25 4.3% 0.13 [-0.51, 0.77] 1.73 0.7 15 2022 Xia K. Y. 3.83 0.53 40 3.91 0.57 40 5.0% -0.14 [-0.58, 0.29] 2022 Zhang P. W. 2.7 0.54 19 3.7 0.34 19 3.6% -2.17 [-2.99, -1.35] 2023 Zhao Z. N. 1.89 0.39 55 1.76 0.34 55 5 2% 0.35 [-0.02, 0.73] Subtotal (95% CI) 149 22.4% 163 -0.27 [-0.94, 0.41] Heterogeneity: Tau² = 0.50; Chi² = 31.25, df = 4 (P < 0.00001); I² = 87% Test for overall effect: Z = 0.78 (P = 0.43) 4.2.3 1 month postoperation 2.64 0.65 2022 Zhang P. W. 19 3.61 0.5 19 3.9% -1.64 [-2.38, -0.89]2023 Wang H. I 1.83 0.56 36 2 0.51 47 5 0% -0.32 [-0.75, 0.12] Subtotal (95% CI) 55 66 8.9% -0.94 [-2.23, 0.35] Heterogeneity: $Tau^2 = 0.78$; $Chi^2 = 8.98$, df = 1 (P = 0.003); $I^2 = 89\%$ Test for overall effect: Z = 1.43 (P = 0.15) 4.2.4 3 months postoperation 2022 Xia K. Y. 2.21 0.59 40 2.33 0.88 40 5.0% -0.16 [-0.60, 0.28] 2022 Zhang P. W. 2.58 0.25 19 3.38 0.27 19 3.2% -3.01 [-3.97, -2.05] Subtotal (95% CI) 59 59 8.2% -1.55 [-4.35, 1.24] Heterogeneity: Tau² = 3.92; Chi² = 28.19, df = 1 (P < 0.00001); I² = 96% Test for overall effect: Z = 1.09 (P = 0.28)4.2.5 Last follow up postoperation -0.07 [-0.66, 0.52] 2018 lia P. 1.79 0.59 4.4% 1.75 0.55 20 24 2020 Ma Y. H. 0.73 0.59 25 4.3% -0.16 [-0.81, 0.48] 15 0.84 0.69 -0.12 [-0.56, 0.32] 2022 Xia K. Y. 1.75 0.55 1.82 0.62 40 5.0% 40 2022 Zhang P. W. 2.57 0.33 19 3.37 0.29 19 3.5% -2.52 [-3.39, -1.65] 2022 Zhao P. 0.5 0.51 30 0.53 0.57 32 4.8% -0.05 [-0.55, 0.44] 2023 Wang H. J. 1.79 0.55 36 1.86 0.36 47 5.0% -0.15 [-0.59, 0.28] 2023 Zhao Z. N. 0.74 0.18 55 0.8 0.21 55 5.2% -0.30 [-0.68, 0.07] Subtotal (95% CI) 215 242 32.0% -0.39 [-0.81, 0.02] Heterogeneity: $Tau^2 = 0.24$; $Chi^2 = 27.55$, df = 6 (P = 0.0001); $I^2 = 78\%$ Test for overall effect: Z = 1.84 (P = 0.07) Total (95% CI) 747 100.0% -0.38 [-0.63, -0.12] 678 Heterogeneity: $Tau^2 = 0.30$; $Chi^2 = 114.64$, df = 21 (P < 0.00001); $I^2 = 82\%$ -2 Ż 0 Test for overall effect: Z = 2.88 (P = 0.004) Favours [VBS] Favours [PKP] Test for subgroup differences: $Chi^2 = 5.22$, df = 4 (P = 0.27), $I^2 = 23.3\%$

FIGURE 5. Forest plots comparing improvement in VAS for pain before the operation, three postoperative days and at one postoperative month, three postoperative months, and the last follow-up time between VBS and PKP. VAS: Visual Analog Scale; VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; SD: Standard deviation; CI: Confidence interval.

month, three articles at three postoperative months, and six articles at the last follow-up. There was no significant difference in Cobb angle at one month and three months. However, VBS showed better Cobb angle correction at three days (SMD= -0.73; 95% CI: -0.98, -0.48; p<0.01; heterogeneity: Tau²=0.00,

Chi²=2.13, df=3, p>0.05, $I^2=0$) and the last followup (SMD= -1.76; 95% CI: -3.06, -0.46; p<0.01; heterogeneity: Tau²=2.52, Chi²=125.21, df=5, p<0.05, $I^2=96\%$; Figure 7). The difference in Cobb angles at the final follow-up between the two operations can be considered clinically significant, although the precise cut-off is unknown.

In addition, cement leakage was reported in three studies, and the analysis showed no significant difference between VBS and PKP (OR=0.81; 95% CI:

0.21, 3.14; p>0.05; heterogeneity: Tau²=0.09, Chi²=5.34, df=2, p>0.05, *I*²=63%; Figure 8).

Publication bias and sensitivity analysis

Funnel plots were constructed to assess publication bias for all the parameters and all funnels were relatively asymmetric (Supplementary Figures 1-3). Sensitivity analysis was performed by randomly excluding one study at a time, and the results remained stable after removing any of the included studies.

ODI (%)

		VBS			РКР		1	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
5.1.1 Preoperation O	DI								
2018 Jia P.	56.64	6.25	20	55.94	5.78	24	5.6%	0.11 [-0.48, 0.71]	
2022 Xia K. Y.	55.65	6.23	40	55.94	5.77	40	6.5%	-0.05 [-0.49, 0.39]	
2022 Zhang P. W.	67	3.02	19	68	3.12	19	5.3%	-0.32 [-0.96, 0.32]	
2022 Zhao P.	81.7	5.04	30	80.94	4.99	32	6.2%	0.15 [-0.35, 0.65]	-
2023 Wang H. J.	77.03	3.8	36	76.36	561	47	6.6%	0.00 [-0.43, 0.44]	
Subtotal (95% CI)			145			162	30.2%	-0.00 [-0.23, 0.22]	•
Heterogeneity: Tau ² =	= 0.00; 0	$Chi^2 =$	1.49, d	f = 4 (P)	= 0.8	3); I ² =	0%		
Test for overall effect	: Z = 0.0)4 (P =	0.97)						
5.1.2 3 days postope	eration (ODI							
2022 Xia K. Y.	20.53	3.85	40	20.51	3.89	40	6.5%	0.01 [-0.43, 0.44]	
2022 Zhang P. W.	18	2.75	19	22	2.64	19	4.9%	-1.45 [-2.18, -0.73]	
Subtotal (95% CI)			59			59	11.4%	-0.69 [-2.12, 0.73]	
Heterogeneity: Tau ² =	= 0.97; 0	$Chi^2 =$	11.41,	df = 1 (P=0.	0007);	$l^2 = 91\%$		
Test for overall effect	Z = 0.9	95 (P =	0.34)						
5.1.3 1 month posto	peration	า							
2022 Zhang P. W.	17	3.02	19	21	3.87	19	5.0%	-1.13 [-1.82, -0.44]	
2023 Wang H. J.	17.06	1.41	36	18.11	1.77	47	6.5%	-0.64 [-1.09, -0.20]	
Subtotal (95% CI)			55			66	11.5%	-0.81 [-1.27, -0.35]	◆
Heterogeneity: Tau ² =	= 0.03; 0	$Chi^2 =$	1.35, d	f = 1 (P)	= 0.2	4); $I^2 =$	26%		
Test for overall effect	: Z = 3.4	19 (P =	0.000	5)					
1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.									
5.1.4 3 months poste	operatio	on							
2018 Jia P.	19.25	4.49	20	19.13	4.99	24	5.6%	0.02 [-0.57, 0.62]	
2022 Xia K. Y.	18.27	2.27	40	18.62	2.21	40	6.5%	-0.15 [-0.59, 0.28]	
2022 Zhang P. W.	16	2.47	19	19	2.47	19	5.0%	-1.19 [-1.88, -0.49]	
Subtotal (95% CI)			79			83	17.2%	-0.40 [-1.05, 0.25]	
Heterogeneity: Tau ² =	= 0.24; 0	$Chi^2 =$	7.83, d	f = 2 (P	= 0.0	2); $I^2 =$	74%		
Test for overall effect	Z = 1.2	22 (P =	0.22)						
5.1.5 Last follow up	ODI								
2018 Jia P.	18.25	3.34	20	18.58	4.14	24	5.6%	-0.09 [-0.68, 0.51]	
2022 Xia K. Y.	17.13	2.61	40	17.31	2.11	40	6.5%	-0.08 [-0.51, 0.36]	
2022 Zhang P. W.	15	2.16	19	18	2.07	19	4.9%	-1.39 [-2.10, -0.67]	
2022 Zhao P.	13.06	2.33	30	13.38	2.08	32	6.2%	-0.14 [-0.64, 0.36]	
2023 Wang H. J.	16.66	0.81	36	16.12	0.79	47	6.5%	0.67 [0.22, 1.12]	
Subtotal (95% CI)			145			162	29.7%	-0.16 [-0.73, 0.40]	
Heterogeneity: Tau ² =	= 0.34; C	Chi ² =	23.53,	df = 4 (P < 0.	0001);	I ² = 83%		
Test for overall effect	Z = 0.5	57 (P =	0.57)						
			407			F 2 2	100.00	0.20 [0.54 0.02]	
Total (95% CI)			483	10 6 -	(n	532	100.0%	-0.28 [-0.54, -0.03]	
Heterogeneity: Tau ² =	= 0.20; C	_hi ² =	61.46,	dt = 16	(P < (0.00001	l); l ² = 74	%	-2 -1 0 1 2
Test for overall effect	Z = 2.2	$22 (P = 0.1)^{2}$	0.03)			0.00	2 60 10	,	Favours [VBS] Favours [PKP]
lest for subgroup dif	rerences	: Chi ²	= 10.6	4, dt =	4 (P =	0.03),	= 62.4%	6	

FIGURE 6. Forest plots comparing improvement in ODI for functional disability before the operation and at three postoperative days, one postoperative month, three postoperative months, and the last follow-up time between VBS and PKP. ODI: Oswestry Disability Index; VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; SD: Standard deviation; CI: Confidence interval.

A systematic review and meta-analysis

	V	BS		РКР		2	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 preoperation C	obb ange	el						
2018 Jia P.	10.79 8	8.49 20	10.54	8.21	24	4.8%	0.03 [-0.56, 0.62]	_ _ _
2022 Xia K. Y.	18.85 3	3.32 40	18.66	3.15	40	5.0%	0.06 [-0.38, 0.50]	+-
2022 Zhang P. W.	17.34 3	3.02 19	17.44	3.02	19	4.8%	-0.03 [-0.67, 0.60]	
2022 Zhao P.	16.4 3	3.73 30	17	3.44	32	4.9%	-0.17 [-0.66, 0.33]	
2023 Wang H. J.	12.91 0	0.71 36	12.45	1.32	47	5.0%	0.41 [-0.02, 0.85]	
2023 Zhao Z. N.	16.12 2	2.04 55	15.89	2.11	55	5.0%	0.11 [-0.26, 0.48]	
Subtotal (95% CI)		200			217	29.4%	0.10 [-0.10, 0.29]	◆
Heterogeneity: Tau ² =	= 0.00; Ch	$i^2 = 3.32, c$	f = 5 (P	= 0.65); $I^2 = 0$)%		
Test for overall effect:	: Z = 0.98	(P = 0.33)						
1.1.2 3 days postope	eration							
2020 Ma Y. H.	6.97 6	5.16 15	12.51	13.86	25	4.7%	-0.47 [-1.12, 0.18]	
2022 Xia K. Y.	11.89 1	1.84 40	14.54	4.21	40	4.9%	-0.81 [-1.26, -0.35]	
2022 Zhang P. W.	9.56 2	2.75 19	12.68	2.75	19	4.7%	-1.11 [-1.80, -0.42]	
2023 Zhao Z. N.	9.67 1	1.82 55	10.88	1.93	55	5.0%	-0.64 [-1.02, -0.26]	T
Subtotal (95% CI)	and the second second second	129		the second se	139	19.4%	-0.73 [-0.98, -0.48]	•
Heterogeneity: Tau ² =	= 0.00; Ch	$i^2 = 2.13, c$	$If = 3 \; (P$	= 0.55); $I^2 = 0$)%		
Test for overall effect:	: Z = 5.71	. (P < 0.000	01)					
1121 month nasta	nonation							
		102 10	10.70	2.52	10	4 70/	0.00[1.50 0.22]	
2022 Zhang P. W.	9.78 3	3.02 19	12.78	3.53	19	4.7%	-0.89 [-1.56, -0.22]	
2023 Wang H. J. Subtotal (95% CI)	7.44	0.8 36	11.5	0.44	47	4.1%	-6.4/[-7.57, -5.37]	
Heterogeneity: Tau ² -	- 15 33. C	$hi^2 - 72.17$	/ df – 1	(P < 0	00001)	· 1 ² - 0.0%	5.00 [5.15, 1.00]	
Test for overall effect:	$\cdot 7 = 131$	(P = 0.19)	, ui – 1	(F < 0.	00001)	, I — 99%		
rest for overall effect.	. 2 - 1.51	(1 = 0.15)						
1.1.4 3 months poste	operation	i i i i i i i i i i i i i i i i i i i						
2018 Jia P.	9.48 7	7.27 20	7.7	6.34	24	4.8%	0.26 [-0.34, 0.85]	
2022 Xia K. Y.	12.21 1	1.34 40	15.23	3.32	40	4.9%	-1.18 [-1.66, -0.70]	_ _
2022 Zhang P. W.	9.93 2	2.47 19	12.54	2.47	19	4.7%	-1.03 [-1.72, -0.35]	
Subtotal (95% CI)		79			83	14.4%	-0.66 [-1.57, 0.25]	
Heterogeneity: Tau ² =	= 0.56; Ch	$i^2 = 14.75,$	df = 2 (P = 0.0	006); I ²	= 86%		
Test for overall effect:	: Z = 1.41	(P = 0.16)						
1.1.5 Last follow up	postopera	ation						
2018 Jia P.	9.59 7	7.71 20	8.02	6.05	24	4.8%	0.23 [-0.37, 0.82]	
2020 Ma Y. H.	8.24 4	4.48 15	12.61	7.21	25	4.7%	-0.68 [-1.33, -0.02]	
2022 Xia K. Y.	11.62 1	1.55 40	14.21	2.77	40	4.9%	-1.14 [-1.62, -0.67]	
2022 Zhang P. W.	9.93 2	2.47 19	11.44	2.32	19	4.7%	-0.62 [-1.27, 0.04]	
2022 Zhao P.	6.2	1.3 30	8.84	1.63	32	4.8%	-1.76 [-2.35, -1.17]	
2023 Wang H. J.	8.34 0	0.75 36	12.5	0.41	47	4.0%	-7.08 [-8.27, -5.90]	
Suptotal (95% CI)		160		(B) (C)	187	28.0%	-1.76 [-3.06, -0.46]	
Heterogeneity: Tau ² =	= 2.52; Ch	$1^{\circ} = 125.21$	dt = 5	(P < 0.	00001)	; 1² = 96%		
Test for overall effect	Z = 2.65	(P = 0.008))					
Total (95% CI)		622			697	100.0%	-100[-148 -051]	
Hotorogonalty Tau ²	1 10. Ch	12 - 224 01	df _ 7	0 (0 < 1	0.000	$1) \cdot 1^2 = 0.4$	o∕	
Test for overall offect	· 7 – 1 02	P = 524.01	(1)	0 (F < 1	.0000.	1, 1 = 94	/0	-'2 -'1 0 1 2
Test for subgroup diff	. 2 - 4.03	$Chi^2 - 32$	1 df -	4 (P ~ C	00001	$1^2 - 88$	2%	Favours [VBS] Favours [PKP]
rescron subgroup un	cicices.		-, ui -			.,, - 00	270	

FIGURE 7. Forest plots comparing improvement in Cobb angle before the operation and at three postoperative days, one postoperative month, three postoperative months, and the last follow-up time between VBS and PKP. VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; SD: Standard deviation; CI: Confidence interval.

Cement leakage

	Experim	ental	Cont	rol		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
2014 Werner CM	15	50	10	50	43.4%	1.71 [0.68, 4.30]			
2020 Ma Y. H.	4	15	6	25	33.2%	1.15 [0.27, 4.99]		_	
2023 Wang H. J.	1	36	9	47	23.4%	0.12 [0.01, 1.00]		-	
Total (95% CI)		101		122	100.0%	0.81 [0.21, 3.14]			
Total events	20		25						
Heterogeneity: Tau ² =	0.89; Ch	$i^2 = 5.3$	4, $df = 2$	P = 0	.07); $I^2 = 0$	63%			100
Test for overall effect:	Z = 0.31	(P = 0.	76)				0.01	Favours [VBS] Favours [PKP]	100

FIGURE 8. Forest plots comparing bone cement leakage between VBS and PKP. VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; CI: Confidence interval.

DISCUSSION

Percutaneous kyphoplasty has been widely utilized as a popular minimally invasive treatment for OVCF and has demonstrated favorable clinical outcomes.[17] In theory, PKP offers advantages, such as reduced cement leakage, increased vertebral body height, and improved Cobb angle correction, attributed to the use of balloon inflation before cement perfusion compared to PVP. However, studies have reported unsatisfactory Cobb angle correction and limited vertebral body height reduction with PKP due to balloon deflation before cement perfusion.^[7,9,18,19] Feltes et al.^[7] conducted a retrospective study evaluating pain relief and vertebral body height restoration through PKP, finding excellent pain relief but limited improvement in vertebral body height restoration. Voggenreiter^[18] also observed a significant loss of fracture reduction after balloon tamp deflation and removal, as assessed by kyphosis angle, anterior height, and medial height of the fractured vertebral body. Therefore, the expected spinal realignment cannot be well achieved by PKP,^[14] resulting in a higher risk of adjacent vertebral body fracture recurrence.[19] In response to these drawbacks, various efforts have been made to develop new devices that prevent the loss of restored fractured vertebral body height after balloon deflation during PKP.[14,20] A cadaver study has shown better results for a metallic implant known as VBS in terms of vertebral augmentation and height restoration compared to PKP.^[14] Vertebral body stenting uses a specially designed catheter-mounted stent that can be implanted and expanded within the vertebral body, remaining in place after balloon deflation to prevent collapse of the vertebral body height.

Wang and Wang^[21] reported a significantly longer operation time for VBS compared to PKP. Although other studies found no significant difference in operation time between VBS and PKP for OVCF, the mean operation time recorded in all these studies was longer for VBS than for PKP.[11,12,22-25] In our meta-analysis, the operation time for VBS is slightly longer than that of PKP. This finding is expected since the VBS procedure involves a thicker puncture needle and a metal bracket on the sleeve, which requires surgeons to exercise greater caution when placing the catheter and expanding the balloon compared to PKP. While the blood loss in VBS was comparable to that in PKP, in our opinion, the thicker puncture needle and cannula used in VBS, along with the longer operation time, may result in slightly more bleeding compared to PKP. Surprisingly, the meta-analysis did not show a significant difference in blood loss

between VBS and PKP. Only Xia et al.^[23] reported a slightly higher mean bleeding volume in VBS (6.9 mL) compared to PKP (5.43 mL), while the difference was not statistically significant. This discrepancy may be attributed to both VBS and PKP being minimally invasive surgeries with minimal bleeding, and the estimation of bleeding volume by surgeons may be subjective and prone to significant error.

Despite both VBS and PKP being widely used for the management of painful OVCF, it remains uncertain whether VBS achieves comparable clinical outcomes to PKP. Unlike PKP, VBS retains the expanded metallic stent within the fractured vertebral body after balloon deflation and withdrawal. Zhang et al.'s^[24] study showed that VBS acquired better clinical outcomes than PKP based on the evaluation of VAS and ODI. However, several other studies have shown no significant difference in clinical outcomes between VBS and PKP.^[11,12,21,22,25] Our meta-analysis indicated that the clinical effect of VBS is equivalent to that of PKP, which is consistent with the majority of the previous cohort studies.

Currently, the existence of significant differences between VBS and PKP in kyphosis correction remains controversial. Werner et al.^[16] found no superior benefits of VBS over PKP regarding kyphotic correction, and VBS was associated with higher pressures during balloon inflation and increased material-related complications. Conversely, Ma et al.[11] found that VBS achieved better kyphosis correction compared to PKP, consistent with several other studies.^[12,21,24] Our analysis revealed that VBS achieved better Cobb angle correction at three postoperative days and the last follow-up compared to PKP, which had statistically significant differences. However, no significant difference was observed at one month and three month postoperatively. In VBS, the stent expands along with the balloon inflation. After the balloon is withdrawn, the stent still plays a supporting role inside the vertebral body, maintaining the height of the vertebral body.[14,26] Once the stent is reinforced with bone cement, its strength significantly increases, reducing the risk of postsurgical vertebral collapse.^[27] Although PKP is an effective surgical method for correcting vertebral kyphosis, the reduction achieved cannot be sustained after balloon deflation due to the presence of osteoporosis, resulting in "secondary collapse" and partial loss of vertebral height.^[14] Therefore, VBS may surpass PKP in terms of vertebral height restoration and kyphosis deformity correction.

A systematic review and meta-analysis

While PKP was designed to reduce the incidence of cement leakage observed in PVP^[4] instances of cement leakage still occur in PKP.[28-30] Whether VBS could decrease the incidence of cement leakage is controversial. Werner et al.[16] found no significant advantage of VBS over PKP with regard to cement leakage. Ma et al.^[11] also found that although VBS can inject a larger volume of bone cement than PKP, there is no difference in the incidence of cement leakage. However, Wang and Wang^[21] discovered that compared to PKP, the VBS group had a higher amount of bone cement injection and a significantly reduced bone cement leakage rate. In our meta-analysis, cement leakage was observed in 19.8% of the vertebral levels treated with VBS and 20.5% of those treated with PKP, but this difference was not significant. The included literature in our study recorded cement leakage rates ranging from 2.8 to 30% in the VBS group and from 19.1 to 24% in the PKP group. These discrepancies may stem from the different evaluation methods used in different studies. Werner et al.[16] used CT evaluation, while Ma et al.^[11] and Wang and Wang^[21] utilized X-ray evaluation. The viscosity of bone cement is closely related to the leakage rate. Wang et al.^[31] found that high-viscosity bone cement led to a lower cement leakage rate in PVP/PKP compared to low-viscosity bone cement in any location, including disc space, epidural space, paravertebral area, and peripheral vein. Other complications were only reported in one study,^[16] which identified that VBS had more complications than PKP, with most of the complications in VBS being material-related, such as failure of the working cannulas, incomplete or no opening of the stent, and balloon rupture. Notably, no postoperative neurologic sequelae were observed in either the VBS or PKP group.

This meta-analysis has certain limitations. First, all the studies included in this analysis were single-center cohort studies, primarily conducted in China, which limits their generalizability to other ethnic groups. Second, there was significant heterogeneity among several parameters across the included studies. Third, there is a lack of high-quality RCTs in this paper. Considering these limitations, further research involving high-quality multicenter studies is necessary to more comprehensively compare the differences between VBS and PKP.

In conclusion, the findings suggest that although there is a statistically significant difference in VAS and ODI, the differences are very minor. Only the Cobb angle correction between the two methods at the last follow-up time has clinically significant difference. No difference was observed in operation time and cement leakage with VBS compared to PKP. The findings suggest that both VBS and PKP yield similar clinical outcomes in terms of VAS and ODI. However, VBS exhibits an advantage in maintaining Cobb angle correction despite its longer operation time.

Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions: Participated in the study conception and design: T.Z., J.L.; Performed the systematic literature search, analyzed the data, drafted the manuscript and conducted the statistical review: T.Z., Y.X.P.; Critically reviewed the manuscript. All authors read and approved the final manuscript: J.L.

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding: The authors received no financial support for the research and/or authorship of this article.

REFERENCES

- 1. Fu X, Li YM, Tian P, Xu GJ, Li ZJ. Comparison between unilateral curved and bilateral straight percutaneous vertebral augmentation in the treatment of osteoporotic vertebral compression fractures: A meta-analysis. Jt Dis Relat Surg 2023;34:237-44. doi: 10.52312/jdrs.2023.967.
- Wang Q, Dong JF, Fang X, Chen Y. Application and modification of bone cement in vertebroplasty: A literature review. Jt Dis Relat Surg 2022;33:467-78. doi: 10.52312/ jdrs.2022.628.
- Huang X, Chang H, Xu H, Chen X, Wang H, Song Y. Comparison of outcomes between percutaneous vertebroplasty and percutaneous kyphoplasty for the treatment of Kümmell's disease: A meta-analysis. Clin Spine Surg 2022;35:276-86. doi: 10.1097/BSD.000000000001269.
- 4. Wang H, Sribastav SS, Ye F, Yang C, Wang J, Liu H, et al. Comparison of percutaneous vertebroplasty and balloon kyphoplasty for the treatment of single level vertebral compression fractures: A meta-analysis of the literature. Pain Physician 2015;18:209-22.
- Wang F, Wang LF, Miao DC, Dong Z, Shen Y. Which one is more effective for the treatment of very severe osteoporotic vertebral compression fractures: PVP or PKP? J Pain Res 2018;11:2625-31. doi: 10.2147/JPR.S179022.
- 6. Li H, Tang Y, Liu Z, Yang H, Zhang Z, Zhang K, et al. The comparison of percutaneous kyphoplasty and vertebroplasty for the management of stage III Kummell disease without neurological symptoms. BMC Surg 2022;22:319. doi: 10.1186/s12893-022-01770-1.
- Feltes C, Fountas KN, Machinis T, Nikolakakos LG, Dimopoulos V, Davydov R, et al. Immediate and early postoperative pain relief after kyphoplasty without significant restoration of vertebral body height in acute osteoporotic vertebral fractures. Neurosurg Focus 2005;18:e5. doi: 10.3171/foc.2005.18.3.6.
- 8. Sun Y, Ma H, Yang F, Tang X, Yi P, Tan M. Clinical efficacy and safety of zoledronic acid combined with

PVP/PKP in the treatment of osteoporotic vertebral compression fracture: A systematic review and metaanalysis of randomized controlled trials. Biomed Res Int 2021;2021:6650358. doi: 10.1155/2021/6650358.

- Verlaan JJ, van de Kraats EB, Oner FC, van Walsum T, Niessen WJ, Dhert WJ. The reduction of endplate fractures during balloon vertebroplasty: A detailed radiological analysis of the treatment of burst fractures using pedicle screws, balloon vertebroplasty, and calcium phosphate cement. Spine (Phila Pa 1976) 2005;30:1840-5. doi: 10.1097/01. brs.0000173895.19334.e2.
- Muto M, Greco B, Setola F, Vassallo P, Ambrosanio G, Guarnieri G. Vertebral body stenting system for the treatment of osteoporotic vertebral compression fracture: Follow-up at 12 months in 20 cases. Neuroradiol J 2011;24:610-9. doi: 10.1177/197140091102400418.
- 11. Ma Y, Zhang S, Yuan K, Zhou T, Luo P, Mo G, et al. Therapeutic effects of percutaneous vertebroplasty and kyphoplasty on osteoporotic vertebral compression fracture. CJTER 2020;24:2170-6. doi: 10.3969/j.issn.2095-4344.2233.
- Zhao P, Ci Y, Li Z, Zhang G, Yao Q. Percutaneous vertebral body stents for osteoporotic vertebral compression fracture. Orthop. J. China 2022;30:314-8.
- Diel P, Röder C, Perler G, Vordemvenne T, Scholz M, Kandziora F, et al. Radiographic and safety details of vertebral body stenting: results from a multicenter chart review. BMC Musculoskelet Disord 2013;14:233. doi: 10.1186/1471-2474-14-233.
- Rotter R, Martin H, Fuerderer S, Gabl M, Roeder C, Heini P, et al. Vertebral body stenting: A new method for vertebral augmentation versus kyphoplasty. Eur Spine J 2010;19:916-23. doi: 10.1007/s00586-010-1341-x.
- Garnon J, Doré B, Auloge P, Caudrelier J, Dalili D, Ramamurthy N, et al. Efficacy of the vertebral body stenting system for the restoration of vertebral height in acute traumatic compression fractures in a non-osteoporotic population. Cardiovasc Intervent Radiol 2019;42:1579-87. doi: 10.1007/s00270-019-02265-y.
- Werner CM, Osterhoff G, Schlickeiser J, Jenni R, Wanner GA, Ossendorf C, et al. Vertebral body stenting versus kyphoplasty for the treatment of osteoporotic vertebral compression fractures: A randomized trial. J Bone Joint Surg [Am] 2013;95:577-84. doi: 10.2106/JBJS.L.00024.
- Yang H, Liu H, Wang S, Wu K, Meng B, Liu T. Review of percutaneous kyphoplasty in China. Spine (Phila Pa 1976) 2016;41 Suppl 19:B52-8. doi: 10.1097/BRS.000000000001804.
- Voggenreiter G. Balloon kyphoplasty is effective in deformity correction of osteoporotic vertebral compression fractures. Spine (Phila Pa 1976) 2005;30:2806-12. doi: 10.1097/01.brs.0000190885.85675.a0.
- Huang MH, Barrett-Connor E, Greendale GA, Kado DM. Hyperkyphotic posture and risk of future osteoporotic fractures: The Rancho Bernardo study. J Bone Miner Res 2006;21:419-23. doi: 10.1359/JBMR.051201.

- Scola A, Gebhard F, Schultheiss M. Preliminary clinical results with vertebral body stenting. Eur Spine J Conference 2010;19:2031. [Abstract]
- 21. Wang H, Wang B. Treatment of osteoporotic vertebral compression fractures with vertebral body stenting system in percutaneous kyphoplasty. J Spinal Surg 2023;21:87-91.
- 22. Jia P, Chen H, Bao L, Feng F, Li J, Tang H. Shortterm efficacy of improved stentoplasty and kyphoplasty in the treatment of osteoporotic vertebral compression fractures. Journal of Clinical and Experimental Medicine 2018;17:1760-1763.
- 23. Xia K, Ci Y, Li Z, Zhang G. A clinical study of percutaneous vertebral body stenting internal fixation for treatment of osteoporotic vertebral compression fracture. J Trad Chin Orthop Trauma 2022;34:1-7.
- 24. Zhang P, Guo H, Yan S, Pang J, Ji G, Wang T, et al. Clinical efficacy of percutaneous balloon-expandable vertebral body stenting for elderly patients with osteoporotic vertebral compression fracture. J Xi'an Jiaotong Univ (Med Sci) 2022;43:63-68.
- 25. Zhao Z, Liu Y, Chen L, Peng T, Jiao Y, Wang Q, et al. Comparison of therapeutic effects between percutaneous vertebral plasty and percutaneous kyphoplasty for osteoporotic vertebral compression fracture. Clin J Med Offic 2023;51:318-320.
- Klezl Z, Majeed H, Bommireddy R, John J. Early results after vertebral body stenting for fractures of the anterior column of the thoracolumbar spine. Injury 2011;42:1038-42. doi: 10.1016/j.injury.2011.04.006.
- 27. Wang D, Zheng S, Liu A, Xu J, Du X, Wang Y, et al. The role of minimally invasive vertebral body stent on reduction of the deflation effect after kyphoplasty: A biomechanical study. Spine (Phila Pa 1976) 2018;43:E341-7. doi: 10.1097/ BRS.00000000002317.
- Chen C, Fan P, Xie X, Wang Y. Risk factors for cement leakage and adjacent vertebral fractures in kyphoplasty for osteoporotic vertebral fractures. Clin Spine Surg 2020;33:E251-5. doi: 10.1097/BSD.000000000000928.
- 29. Ren H, Feng T, Cao J, Hu Y, Yu D, Pan S, et al. A retrospective study to evaluate the effect of dynamic fracture mobility on cement leakage in percutaneous vertebroplasty and percutaneous kyphoplasty in 286 patients with osteoporotic vertebral compression fractures. Med Sci Monit 2022;28:e935080. doi: 10.12659/MSM.935080.
- 30. Li M, Zhang T, Zhang R, Zhang H, Zhang D, Hu N, et al. Systematic retrospective analysis of risk factors and preventive measures of bone cement leakage in percutaneous kyphoplasty. World Neurosurg 2023;171:e828-36. doi: 10.1016/j.wneu.2022.12.117.
- 31. Wang Q, Sun C, Zhang L, Wang L, Ji Q, Min N, et al. High- versus low-viscosity cement vertebroplasty and kyphoplasty for osteoporotic vertebral compression fracture: A meta-analysis. Eur Spine J 2022;31:1122-30. doi: 10.1007/s00586-022-07150-w.

A systematic review and meta-analysis





SUPPLEMENTARY FIGURE 2. Funnel plots of publication bias in improvement in VAS for pain and improvement in the ODI scores for functional disability between VBS and PKP.

VAS: Visual Analog Scale; ODI Oswestry Disability Index; SE: Standard error; SMD: Standard mean difference; VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty.



SUPPLEMENTARY FIGURE 3. Funnel plots of publication bias in the correction of the Cobb angle and bone cement leakage between VBS and PKP.

SE: Standard error; SMD: Standard mean difference; VBS: Vertebral body stenting; PKP: Percutaneous kyphoplasty; OR: Odds ratio.